Floatz logo

Cladribine

Multiple Sclerosis

University Hospital, Strasbourg, FranceSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
76/ 100
Competitive Position
65/ 100

Competitive context

182 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Teriflunomide
Sanofi
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Natalizumab
Biogen
Phase 4BB

View all 50 →

Same molecule, other indications

Cladribine is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
lymphoblastic lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
myeloid neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →